8. May 2024
Athebio AG appoints Thomas Huber, PhD, as CEO
Read more
15. December 2023
Athebio AG appoints Dr. Jens Hennecke to its Board of Directors
Read more
18. September 2023
POINT Biopharma and Athebio Announce Partnership to Develop Designed Ankyrin Repeat Protein Targeted Radioligands
Read more
20. July 2023
Shareholders of Athebio AG elect Dr. Hans-Peter Gerber as new member of the Board of Directors
Read more
28. March 2023
Athebio Enters Development and License Agreement with Acuitas Therapeutics
Read more
20. March 2023
Athebio AG appoints Dr. Hans-Peter Gerber as Scientific Advisor
Read more
15. September 2022
Athebio Enters Collaboration Agreement with 3T Biosciences
Read more
4. February 2022
Athebio Enters Research Agreement with REGENXBIO
Read more
6. January 2022
Athebio AG appoints Dr. Victor Levitsky as Scientific Adviso
Read more